TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine
The transient receptor potential vanilloid type-1 receptor (TRPV1) and the neuropeptides calcitonin gene-related peptide (CGRP) and substance P (SP) appear to be differently involved in migraine pain. A role of neurovascular scalp structures is also suggested by several data. We performed a quantitative study of TRPV1-like immunoreactive (LI), CGRP-LI and SP-LI innervation of scalp arterial samples from patients affected with chronic migraine (CM). Short segments of scalp arteries were collected from 17 participants undergoing vascular surgery for treatment-resistant CM and from 6 controls who underwent neurosurgery for various indications. The immunoreactivity of the arterial innervation to TRPV1, CGRP, SP and to the pan-neuronal marker protein gene product 9.5 (PGP9.5) was examined. Immunoreactive nerve fibres in vessel cross-sections were quantified by computerised image analysis. A significant increase of TRPV1-LI nerve fibres was found in the arterial wall from CM compared with control patients (p<0.05), while no significant difference was found for CGRP and SP. This study yields the first evidence for the existence of a TRPV1-LI innervation in human scalp arteries and provides the first quantitative assessment of the TRPV1-LI, CGRP-LI and SP-LI innervation of those vessels. The increase of TRPV1-LI periarterial nociceptive fibres of scalp arteries may represent, at least in some participants, a structural condition favouring CM (and possibly migraine), for example, by causing a higher sensitivity to algogenic agents..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
Journal of neurology, neurosurgery and psychiatry - 86(2015), 4, Seite 393-397 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Del Fiacco, Marina [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1136/jnnp-2014-308813 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1963175948 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1963175948 | ||
| 003 | DE-627 | ||
| 005 | 20230714160637.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jnnp-2014-308813 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1963175948 | ||
| 035 | |a (DE-599)GBVOLC1963175948 | ||
| 035 | |a (PRQ)c1729-b2f7fd696176aa36319e20e69088b39d4d10c92158ba38967c6c8d9c628aa1410 | ||
| 035 | |a (KEY)0013960220150000086000400393trpv1cgrpandspinscalparteriesofpatientssufferingfr | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Del Fiacco, Marina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The transient receptor potential vanilloid type-1 receptor (TRPV1) and the neuropeptides calcitonin gene-related peptide (CGRP) and substance P (SP) appear to be differently involved in migraine pain. A role of neurovascular scalp structures is also suggested by several data. We performed a quantitative study of TRPV1-like immunoreactive (LI), CGRP-LI and SP-LI innervation of scalp arterial samples from patients affected with chronic migraine (CM). Short segments of scalp arteries were collected from 17 participants undergoing vascular surgery for treatment-resistant CM and from 6 controls who underwent neurosurgery for various indications. The immunoreactivity of the arterial innervation to TRPV1, CGRP, SP and to the pan-neuronal marker protein gene product 9.5 (PGP9.5) was examined. Immunoreactive nerve fibres in vessel cross-sections were quantified by computerised image analysis. A significant increase of TRPV1-LI nerve fibres was found in the arterial wall from CM compared with control patients (p<0.05), while no significant difference was found for CGRP and SP. This study yields the first evidence for the existence of a TRPV1-LI innervation in human scalp arteries and provides the first quantitative assessment of the TRPV1-LI, CGRP-LI and SP-LI innervation of those vessels. The increase of TRPV1-LI periarterial nociceptive fibres of scalp arteries may represent, at least in some participants, a structural condition favouring CM (and possibly migraine), for example, by causing a higher sensitivity to algogenic agents. | ||
| 540 | |a Nutzungsrecht: © Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. | ||
| 650 | 4 | |a Calcitonin Gene-Related Peptide - metabolism | |
| 650 | 4 | |a TRPV Cation Channels - metabolism | |
| 650 | 4 | |a Calcitonin Gene-Related Peptide - genetics | |
| 650 | 4 | |a Substance P - metabolism | |
| 650 | 4 | |a Substance P - genetics | |
| 650 | 4 | |a TRPV Cation Channels - genetics | |
| 650 | 4 | |a Nerve Fibers - metabolism | |
| 650 | 4 | |a Migraine Disorders - genetics | |
| 650 | 4 | |a Scalp - blood supply | |
| 650 | 4 | |a Migraine Disorders - metabolism | |
| 650 | 4 | |a Arteries - metabolism | |
| 650 | 4 | |a Calcitonin | |
| 650 | 4 | |a Risk factors | |
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a Analysis | |
| 650 | 4 | |a Care and treatment | |
| 650 | 4 | |a Substance P | |
| 650 | 4 | |a Usage | |
| 700 | 1 | |a Quartu, Marina |4 oth | |
| 700 | 1 | |a Boi, Marianna |4 oth | |
| 700 | 1 | |a Serra, M Pina |4 oth | |
| 700 | 1 | |a Melis, Tiziana |4 oth | |
| 700 | 1 | |a Boccaletti, Riccardo |4 oth | |
| 700 | 1 | |a Shevel, Elliot |4 oth | |
| 700 | 1 | |a Cianchetti, Carlo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology, neurosurgery and psychiatry |d London : BMJ Publishing Group, 1944 |g 86(2015), 4, Seite 393-397 |w (DE-627)129078883 |w (DE-600)3087-9 |w (DE-576)014411466 |x 0022-3050 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2015 |g number:4 |g pages:393-397 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1136/jnnp-2014-308813 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25288608 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PSY | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_21 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2410 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4306 | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2015 |e 4 |h 393-397 | ||